Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi chairman joins Pertinax Pharma

Nigel Brooksby will drive the commercialisation of the company as chairman

Pertinax Pharma has appointed Nigel Brooksby as its new chairman, a role that will see him help drive the commercialisation of the company by assisting in corporate strategic and business developments.

During his 38-year career in the pharmaceutical industry, Brooksby has served in roles such from medical sales representative to chairman.

He has held senior appointments in Wellcome - now GSK, Pfizer and as chairman and MD at Sanofi UK and Ireland and as a member of the Sanofi Executive Committee in Europe and America.

Michele Barbour, founder and chief scientific officer, Pertinax Pharma, said: “We are delighted that Nigel has chosen to join our board.

“His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand.

“We look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as bring the benefits of our patented and commercialised Pertinax technology to the healthcare sector.”

24th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics